ISRG$542.995
Chart
Performance
Key Stats
AI ISRG Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyIntuitive Surgical (ISRG) demonstrates strong fundamental performance and is well-positioned within the growing minimally invasive surgery market. However, current valuation metrics and recent technical indicators suggest a cautious short-term outlook, favoring a 'Buy' rather than 'Strong Buy' rating for a balanced approach.
Thematic
ISRG benefits from robust secular growth trends in healthcare, particularly the increasing adoption of minimally invasive procedures and robotic-assisted surgery. Technological advancements and an aging global population further bolster its long-term thematic appeal.
Fundamental
ISRG exhibits strong financial health with consistent revenue growth and improving profitability. Its balance sheet is robust, and free cash flow generation remains solid, although the current valuation multiples are on the higher side.
Technical
The stock has experienced a significant price decline, breaking below key moving averages. While oscillators suggest potential oversold conditions, the overall trend is currently bearish, indicating caution.
| Factor | Score |
|---|---|
| Robotic Surgery Adoption | 95 |
| Healthcare Technology Advancements | 90 |
| Aging Global Population | 85 |
| Emerging Market Expansion | 75 |
| Regulatory and Reimbursement Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 90 |
| Growth | 80 |
| Balance Sheet Health | 95 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Surprises
Intuitive Surgical (ISRG) has a strong track record of exceeding earnings per share (EPS) estimates, with positive surprises in 10 out of the last 12 reported quarters. The most recent quarter (2025 Q1) saw an EPS surprise of 23.19%.
Growth at a Reasonable Price (PEG)
The TTM P/E ratio is 67.2, and with an estimated EPS for 2025 of $1.72 (Q2 estimate), the forward P/E remains elevated. However, considering the company's consistent growth, the PEG ratio, if calculated with projected growth rates, could present a more favorable picture, though specific growth rate data is not directly provided in the input.
Bearish Points (7)
High Valuation Multiples
The TTM P/E ratio of 68.05 and a Price-to-Sales (P/S) ratio of 19.1 indicate a high valuation. While growth justifies some premium, these multiples suggest that a significant portion of future growth is already priced into the stock, increasing downside risk if growth expectations are not met.
Slowing Revenue Growth Trends
While revenue for Q4 2024 was $8.35 billion, an increase from Q4 2023 ($7.12 billion), the net margin has fluctuated. Year-over-year quarterly revenue growth rates, while not explicitly detailed in a comparative table, need close monitoring to ensure sustained expansion.
Calendar
October 2025
17
Next Earnings Date
H: $2.15
A: $1.99
L: $1.85
H: 2.47B
A: 2.40B
L: 2.34B
Profile
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Seasonals
Price Target
586.42 USD
The 39 analysts offering 1 year price forecasts for ISRG have a max estimate of 685.00 and a min estimate of 350.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Global healthcare conglomerate with a significant medical device segment, including direct robotic surgery competitors (Ottava, Monarch platforms) to ISRG.
Weight: 95
One of the largest medical technology companies, a direct competitor to ISRG with its Hugo robotic-assisted surgery system and a broad range of surgical instruments.
Weight: 92
A leader in medical technology, particularly in orthopedics with its MAKO robotic-arm assisted surgery system, reflecting innovation in surgical robotics.
Weight: 88
Major orthopedic device company, a competitor in specific robotic surgery segments with its ROSA robotic system for knee and hip replacements.